Division of Infectious Diseases, Mayo Clinic, Phoenix, Arizona, USA.
Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona, USA.
BMJ Case Rep. 2021 Jan 19;14(1):e237085. doi: 10.1136/bcr-2020-237085.
Herein, we report a case of a 68-year-old woman receiving ibrutinib for chronic lymphocytic leukaemia, who presented with septic shock and a progressive necrotic lesion on her nose. Surgical pathology of the nasal lesion revealed evidence of tissue necrosis, and both tissue and blood culture grew A diagnosis of ecthyma gangrenosum was made. Additional investigations also led to the discovery of invasive pulmonary aspergillosis. To our knowledge, this is the first case of ecthyma gangrenosum secondary to sepsis and concurrent invasive pulmonary aspergillosis associated with ibrutinib use.
在此，我们报告一例 68 岁女性因慢性淋巴细胞白血病接受伊布替尼治疗后出现脓毒性休克和鼻渐进性坏死性病变。鼻病变的手术病理显示有组织坏死的证据，组织和血液培养均生长出 坏死性溃疡。诊断为坏疽性脓皮病。进一步的调查还发现侵袭性肺曲霉病。据我们所知，这是首例与伊布替尼使用相关的脓毒症继发坏疽性脓皮病和合并侵袭性肺曲霉病。
